Higher-than-usual doses of radiation in the treatment of inoperable lung cancer can be safely combined with immunotherapy ...

Investigators are using MET immunohistochemistry testing and FDA-approved profiling tools to personalize care and address ...

Two research articles published in Nature Genetics shed new light on the cellular complexity of glioblastoma, the most ...

The first patient was dosed in the SKYBRIDGE study assessing peluntamig with Tecentriq for advanced small cell lung cancer ...

Raymond Osarogiagbon, MD, highlights the potential benefits of increasing screening rates for patients diagnosed with lung cancer and the broader US health care system.

Search for other works by this author on: ...

A rare cell type ... on the virus (lung inflammation) from spiraling out of control to endanger patients. Macrophages are known to be the first responders to infection, as large immune cells ...

One potential cause of multiple solid lesions in the lungs is synchronous multiple primary non-small cell lung cancer (SMPNSCLC). Another possible cause of multiple solid lesions in the lungs is ...

Meanwhile, CSF cytology turned negative ... The treatment of LM remains a significant challenge for most cancers, including breast cancer, except for certain tumors, such as lung adenocarcinoma, for ...

NICE is unable to make a recommendation on tislelizumab (Tevimbra) in combination for untreated advanced non-small-cell lung cancer in adults. This is because the company did not provide an evidence ...

Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma, affecting tens of thousands of people each year in the U.S. While many patients respond well to initial treatment ...

"Optune Lua is an innovative and urgently needed new approach for treating metastatic non-small cell lung cancer," said Joachim Aerts, M.D., a LUNAR investigator and Professor of Pulmonary ...